Association of single-nucleotide polymorphism 3 and c.553G>T of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in hiv-infected individuals in Taiwan

Clin Infect Dis. 2009 Mar 15;48(6):832-5. doi: 10.1086/597099.

Abstract

We investigated the relationship between hypertriglyceridemia and the single-nucleotide polymorphisms (SNPs) on APOA5 in human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART) in Taiwan. Receipt of protease inhibitor-based HAART, high baseline triglyceride levels, and carriage of APOA5 SNP3 or c.553G>T variants or APOA5 SNP1T/SNP2G/SNP3C/c.553T haplotype were statistically significantly associated with development of extreme hypertriglyceridemia (triglyceride level, >500 mg/dL).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antiretroviral Therapy, Highly Active / adverse effects*
  • Apolipoprotein A-V
  • Apolipoproteins A / genetics*
  • Female
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / adverse effects*
  • HIV Protease Inhibitors / therapeutic use
  • Haplotypes
  • Humans
  • Hypertriglyceridemia / genetics*
  • Male
  • Middle Aged
  • Point Mutation
  • Polymorphism, Single Nucleotide*
  • Taiwan
  • Young Adult

Substances

  • APOA5 protein, human
  • Apolipoprotein A-V
  • Apolipoproteins A
  • HIV Protease Inhibitors